19543565|t|[Atypical antipsychotics and CATIE-AD. Is this a turning point?].
19543565|a|The Clinical Antipsychotic Trials of Intervention Effectiveness -Alzheimer Disease (CATIE-AD) is the first 36 weeks effectiveness trial of atypical antipsychotics in patients with Alzheimer's disease presenting with behavioral and psychiatric symptoms of dementia (BPSD). There were no significant differences between atypical antipsychotics and placebo in effectiveness measures which also included a cost-benefit analysis. This article not only reviews this landmark study but also summarizes the complex relationship between antipsychotics and BPSD during the last years.
19543565	29	37	CATIE-AD	Disease	MESH:D000544
19543565	131	148	Alzheimer Disease	Disease	MESH:D000544
19543565	150	158	CATIE-AD	Disease	MESH:D000544
19543565	232	240	patients	Species	9606
19543565	246	265	Alzheimer's disease	Disease	MESH:D000544
19543565	282	320	behavioral and psychiatric symptoms of	Disease	MESH:D001523
19543565	321	329	dementia	Disease	MESH:D003704
19543565	331	335	BPSD	Disease	MESH:D001523
19543565	613	617	BPSD	Disease	MESH:D001523

